We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$7.91B
AUM Growth
-$1.41B
Cap. Flow
-$1B
Cap. Flow %
-12.68%
Top 10 Hldgs %
40.65%
Holding
174
New
35
Increased
19
Reduced
37
Closed
35

Top Buys

Rank Stock Value
1
LABP
Landos Biopharma, Inc. Common Stock
LABP
+$194M
2
BBIO icon
BridgeBio Pharma
BBIO
+$68.7M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$68.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$62.1M
5
SWTX
SpringWorks Therapeutics
SWTX
+$52.6M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$116M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$100M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$90.4M
4
NVTA
Invitae Corporation
NVTA
+$87.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$87.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.08%
2 Financials 0.47%
3 Industrials 0.2%
4 Consumer Discretionary 0.02%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
26
Relay Therapeutics
RLAY
$4B
$69.8M 0.88%
2,018,097
-311,310
-13% -$13.5M
CHRS icon
27
Coherus Oncology
CHRS
$217M
$68.6M 0.87%
4,697,612
+25,776
+0.6% +$438K
MGNX icon
28
MacroGenics
MGNX
$236M
$68.4M 0.87%
2,148,060
+887,000
+70% +$21.5M
CERE
29
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$63.7M 0.81%
4,643,095
+99,033
+2% +$1.45M
LONA
30
LeonaBio Inc
LONA
$67M
$63M 0.8%
342,592
+31,111
+10% +$6.86M
ESTA icon
31
Establishment Labs
ESTA
$2.7B
$61.7M 0.78%
987,287
+290,654
+42% +$16.8M
KDMN
32
DELISTED
Kadmon Holdings, Inc.
KDMN
$61.1M 0.77%
15,711,334
– –
NARI
33
DELISTED
Inari Medical, Inc. Common Stock
NARI
$60.5M 0.76%
565,113
-103,387
-15% -$10.7M
QTNT
34
DELISTED
Quotient Limited Ordinary Shares
QTNT
$59.6M 0.75%
405,020
– –
MORF
35
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$59.4M 0.75%
938,140
+451,140
+93% +$20.7M
ATNX
36
DELISTED
Athenex, Inc. Common Stock
ATNX
$57.3M 0.73%
676,623
– –
RXDX
37
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$55.4M 0.7%
+3,314,032
New +$68.4M
RAPT
38
DELISTED
RAPT Therapeutics
RAPT
$55M 0.7%
309,685
+112,500
+57% +$18.5M
VRCA icon
39
Verrica Pharmaceuticals
VRCA
$92.9M
$54.7M 0.69%
361,041
+20,000
+6% +$2.77M
CRNX icon
40
Crinetics Pharmaceuticals
CRNX
$8.88B
$51.6M 0.65%
3,659,381
– –
VERU icon
41
Veru
VERU
$35.5M
$48M 0.61%
445,134
+120,134
+37% +$15.1M
EXAS
42
DELISTED
Exact Sciences
EXAS
$46.6M 0.59%
+353,523
New +$48.4M
VYNE icon
43
VYNE Therapeutics
VYNE
$46.4M 0.59%
7,527
+1,172
+18% +$8.5M
KOD icon
44
Kodiak Sciences
KOD
$2.46B
$44.1M 0.56%
389,008
-362,525
-48% -$49.5M
TARS icon
45
Tarsus Pharmaceuticals
TARS
$2.52B
$41.1M 0.52%
1,296,416
– –
DBVT
46
DBV Technologies
DBVT
$799M
$41M 0.52%
769,551
+110,000
+17% +$5.83M
ALLO icon
47
Allogene Therapeutics
ALLO
$614M
$40.4M 0.51%
1,143,790
– –
ARNA
48
DELISTED
Arena Pharmaceuticals Inc
ARNA
$39.9M 0.5%
575,007
– –
BEAM icon
49
Beam Therapeutics
BEAM
$2.71B
$37.8M 0.48%
+537,635
New +$51.1M
LYRA
50
DELISTED
LYRA THERAPEUTICS INC
LYRA
$37.3M 0.47%
64,451
– –
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Perceptive Advisors held 174 positions worth $7.91B, down 15% from $9.32B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Perceptive Advisors withdrew a net $1B in Q1 2021, closing 35 positions and reducing 37 holdings. Its most notable exit was Novavax, an estimated $116M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Landos Biopharma, Inc. Common Stock worth $141M.

  • Perceptive Advisors's largest Q1 2021 buy was Landos Biopharma, Inc. Common Stock: 1,486,992 shares worth $141M.
  • Perceptive Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $68.7M increase.
  • Perceptive Advisors's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $100M.
  • Perceptive Advisors fully exited Novavax in Q1 2021, selling an estimated $116M.
  • Perceptive Advisors's ten largest holdings make up 41% of its $7.91B portfolio in Q1 2021.
  • Perceptive Advisors opened 35 new positions and closed 35 in Q1 2021.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $7.91B.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.